Department of Health and Social Care (DHSC) has issued a medicine supply notification for Oxcarbazepine (Trileptal) 300mg and 600mg tablets on
Wednesday (14 June).
It has notified that the Oxcarbazepine (Trileptal) 300mg tablets will be out of stock from late June 2023 until mid-July 2023 and Oxcarbazepine (Trileptal) 600mg
tablets are out of stock until mid-July 2023.
However, generic oxcarbazepine 300mg and 600mg tablets remain available and will be able to support increased demand.
"Oxcarbazepine (Trileptal) 150mg tablets and generic oxcarbazepine 150mg tablets remain available but cannot support the increase in demand," said DHSC.
"Oxcarbazepine (Trileptal) 60mg/ml oral suspension remains available but cannot meet an increase in demand."
As we take look back over the past year and reflect on what we have achieved, it's also important that we look ahead to new challenges and opportunities that
may arise in 2023. We have seen remarkable innovation across the industry in 2022, from big break throughs in treatment and improvements to patient outcomes, to how
the industry is working with big data and technology. But it's fair to say that these achievements came paired with just as many challenges including a continued
talent shortage, hangovers from the pandemic, increasing pressures to innovate and ongoing macroeconomic challenges.
As we head into 2023, I expect these existing challenges to continue alongside new ones, but I also anticipate more opportunities to present themselves. At
Pharamanovia, we predict that the key trends set to catalyse the pharmaceutical and healthcare industries in 2023 include break through innovations, technology,
big data, sustainability, ongoing policy changes and a shift in investment due to inflation.
Utilising big data and tech
Technology has been recognised as one of the industry's biggest tools for many years, and I don't expect to see the pace of how we use technology in healthcare and
pharma to slow down any time soon. In 2023, I expect that we will see further automation in the way we work, with an increase in digital engagement and healthcare
providers leveraging remote access further.
The Royal Pharmaceutical Society (RPS) has urged the government to amend medicines legislation to allow pharmacists to make minor amendments to a prescription
without any protocol being needed.
RPS wants to see a change in the law that makes the whole process of supply of medicines easier and quicker, enabling pharmacists to use their knowledge and expertise
in medicines to better support patients.
"At present a prescription can only be changed by a prescriber, which causes unnecessary workload for GPs and delays for patients," said RPS.
RPS President Professor Claire Anderson said: "We want to see all pharmacists across the UK able to supply a different quantity, strength or formulation of a medicine
(for example changing capsules to tablets) when required, to avoid unnecessary bureaucracy and the need for an SSP to be developed, signed and authorised by a
Minister. In effect it would mean that pharmacists can help patients straight away - it would future proof the problem to some degree.
As the countdown to the next UK election begins, the King's Fund has identified three priorities to improve public health.
The national action would be taken by the future government to fix the "NHS and social care" in the country.
The health policy think tank said it would prioritise "improving access to out-of-hospital care", making "careers in health and social care" more attractive
and tackling the biggest risk factors affecting people's health.
It highlighted that workforce crisis is one of the biggest challenges faced by the National Health Service (NHS) and social care services in England while
citing "years of poor planning and fragmented responsibilities" as the reason for widespread staff shortages.
As per the King's Fund's data, there were more than 125,000 vacancies across the NHS workforce in England in October 2023, not including primary care vacancies
such as GPs, and 152,000 vacant posts in the adult social care workforce.
The British Medical Association (BMA) on Wednesday announced that 33,869 junior doctors have voted in favour of extending the industrial action and the
use of action short of strike (ASOS).
With a turnout of 62 per cent, their demand stems from the ongoing campaign for complete pay restoration. The new mandate will last till September 19, starting
on 3 April.
The BMA junior doctors committee co-chairs, Dr Robert Laurenson and Dr Vivek Trivedi, expressed frustration at the year-long strike action, highlighting the
government's avoidance tactics to tackle soaring waiting lists, access to GPs and staff shortages.
"The government should see the urgency of the situation. Rather than waste time dragging out talks, they can come forward with a credible offer on pay right now. "
"Instead, they could be celebrating a revitalised and reinvigorated junior doctor workforce, one that feels that their value has started to be restored. That
would be an achievement worth celebrating for everyone and begin to finally turn the tide on the deteriorating workforce crisis," they said.
Atorvastatin, a medicine to treat high blood cholesterol, is the most dispensed drug with 59 million items in England in 2022/23, revealed the NHS Business
Services Authority (NHSBSA) on Thursday (8 June).
While Apixaban (an anticoagulant) was the drug with the highest costs of £430 million. Apixaban 5mg tablets had the largest increase in cost between 2021/22 and
2022/23 in England, with an increase of £280 million.
NHSBSA's annual statistics report 'Prescription Cost Analysis-England 2022/23' published also has revealed an eight per cent rise in the prescription items that
were dispensed in the community in England.
The report highlighted that in 2022/23, 1.18 billion prescription items were dispensed at a cost of £10.4 billion in the community in England, witnessing an
increase of eight per cent from £9.69 billion in 2021/22.
The Department of Health and Social Care (DHSC) has suggested Estradiol patch as an alternative for patients who use 1 pump of Oestrogel daily.
DHSC has updated Annex A of SSP022 and SSP023 for Oestrogel Pump-Pack 0.06 per cent gel to include a dose conversion to a specific alternative Estradiol patch.
Previously, only dose conversions for patients using 2 to 4 pumps daily were included in Annex A of SSP022 and SSP023.
Separately, the supporting guidance for three SSPs which allow quantity restriction have been updated to reflect the requirement to endorse the reduced quantity
supplied in accordance with these SSPs.
SSP019 - Oestrogel pump-pack 0.06% gel
SSP020 - Ovestin 1mg cream
SSP021 - Premique low dose 0.3mg/1.5mg modified release tablets
"When endorsing an SSP for a reduced quantity, contractors must ensure that the correct SSP number is endorsed along with the product name and the reduced
quantity supplied in accordance with the SSP," said PSNC.
Besins Healthcare has acquired a pharmaceutical manufacturing site in Drogenbos, Belgium to boost the production of hormonal products including Oestrogel.
Currently, the site which is being used as one of two manufacturing sites for their gel products [the other site being in France], is a strategic purchase to allow
Besins Healthcare to increase production of its own products, offering greater efficiencies and greater integration into the company's supply line.
"In the past year, demand for hormone replacement therapy (HRT) treatment in the United Kingdom and Ireland has dramatically increased, resulting in regrettable
disruption to supply of Oestrogel. We are looking at a range of options for increasing supplies of this product in the short, medium and longer term," said Alexandre
Besins, joint CEO for Besins Healthcare.
"Besins strongly believes that by re-integrating our manufacturing capabilities we will have better control over our ability to meet demand and live up to the trust
that HCPs and patients have put in us."
The British Generic Manufacturers Association (BGMA) has warned that England's 42 integrated care boards (ICBs) may need to allocate an extra £37 million
from their budgets annually for the next five years due to the spiralling tax rates.
The government's Voluntary Scheme for Branded Medicines Pricing and Access (VPAS) rebate rate increased more than five-fold in the past two years, the BGMA said
in its white paper released on Monday (October 30).
The report, conducted by consultancy firm Conclusio in consultation with local NHS leaders, examined the potential effects of the VPAS on ICB budgets.
BGMA said that due to the elevated VPAS rate, each ICB in England will experience significant increases in expenses for branded generics and biosimilars
annually - a consequence of reduced competition.
"Patients deserve choice, but wherever they go they will find vacant nursing posts and overstretched services," responded Professor Pat Cullen, RCN
General Secretary and Chief Executive, to the introduction of the new pilot scheme for out-of-hospital patient care.
The NHSE and the DHSC have announced a new pilot scheme commencing in autumn "offering patients a choice of where they receive out-of-hospital care".
Under the initiative, individuals requiring treatment outside of hospitals will have the opportunity to select from a range of providers across both the NHS
and the independent sector.
Patients can select their care provider for in-hospital consultant-led services post-GP consultation, offering a choice from at least 5 providers with details
on waiting times, distance, and quality.